Summary:
A US, phase 3, multicenter, randomiozed, double-blinc, placebo-controlled clinical trial of Fasedienol Nasal Spray for the acute treatment of anxiety induced by a public speaking challenge in adult subjects with social anxiety disorder, with an open-label estension
Qualified Participants Must:
• Must be between 18-65 years of age
• have social anxiety symptoms
• must not be taking an antidepressant
• must not have a diagnosis of bipolar, schizoaffective disorder, or eating disorder
Qualified Participants May Receive:
Reimbursement for time and travel of $100.00 for each completed visit.